TRACON Pharmaceuticals, Inc. Common Stock
TCON
TCON: TRACON Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer and utilizing its cost efficient, contract research organization (CRO) independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the United States. The company's drug candidate includes Envafolimab, TRC102, TRC253, and Bispecific Antibodies.
moreShow TCON Financials
Recent trades of TCON by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by TCON's directors and management
Government lobbying spending instances
New patents grants
-
Patent Title: Use of anti-endoglin antibodies for treating ocular fibrosis Jul. 02, 2019
-
Patent Title: Antibody formulations and uses thereof Feb. 05, 2019
-
Patent Title: Anti-endoglin antibodies and uses thereof Dec. 18, 2018
-
Patent Title: Endoglin antibodies Apr. 17, 2018
-
Patent Title: Anti-endoglin antibodies and uses thereof Mar. 27, 2018
-
Patent Title: Endoglin antibodies Dec. 13, 2016
-
Patent Title: Endoglin antibodies Oct. 06, 2015
-
Patent Title: Endoglin antibodies Dec. 17, 2013
-
Patent Title: Endoglin antibodies Jul. 17, 2012
-
Patent Title: Antifolate agent combinations in the treatment of cancer Sep. 13, 2011
Federal grants, loans, and purchases
Followers on TCON's company Twitter account
Number of mentions of TCON in WallStreetBets Daily Discussion
Recent insights relating to TCON
Recent picks made for TCON stock on CNBC
ETFs with the largest estimated holdings in TCON
Flights by private jets registered to TCON